| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 688670 | 金克 | 21.88 | -2.54% | 3.89万 | 8544.14万 | | 688163 | 赛伦生物 | 21.69 | -2.08% | 7606.74 | 1661.26万 | | 301080 | 百普赛斯 | 54.10 | -2.05% | 4 8569.1 | 4666.97万 | | 920575 | 康乐卫士 | 8.94 | -1.97% | 4.39万 | 3951.81万 | | 300357 | 我武生物 | 29.23 | -1.52% | 4.45万 | 1.31亿 | | 002581 | ST未名 | 7.62 | -1.42% | 4.02万 | 3070.38万 | | 301393 | 吴帆生物 | 50.00 | -1.34% | 6085.0 | 3050.64万 | | 002773 | 康弘药业 | 30.76 | -1.32% | 4.95万 | 1.53亿 | | 30 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 上海赛伦生物技术股份有限公司（以下简称"公司"）分别于2025年4月25日召开了第四届董事会第六次 会议、第四届监事会第五次会议，于2025年5月16日召开了2024年年度股东大会，审议通过了《关于续 聘公司2025年度审计机构的议案》，同意续聘天职国际会计师事务所（特殊普通合伙）（以下简称"天 职国际"）为公司2025年度审计机构。具体内容详见公司2025年4月26日在上海证券交易所网站 （www.sse.com.cn）披露的《关于续聘2025年度审计机构的公告》（公告编号：2025-012）。 近日，公司收到天职国际出具的《关于变更签字注册会计师的告知函》，现将具体情况公告如下： 一、本次签字注册会计师变更的基本情况 天职国际作为2025年度财务报告审计机构与内部控制审计机构，原委派郭海龙为项目合伙人、金园为签 字注册会计师、张磊为项目质量复核人。由于天职国际内部工作调整，金园不再担任年报签字注册会计 师，现委派陈俞宜接替金园作为公司年报签字注册会计师，继续完成相关工作。 ...

证券代码：688163 证券简称：赛伦生物 公告编号：2025-029 上海赛伦生物技术股份有限公司 关于变更签字注册会计师的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海赛伦生物技术股份有限公司（以下简称"公司"）分别于 2025 年 4 月 25 日召开了第四届董事会第六次会议、第四届监事会第五次会议，于 2025 年 5 月 16 日召开了 2024 年年度股东大会，审议通过了《关于续聘公司 2025 年度审 计机构的议案》，同意续聘天职国际会计师事务所（特殊普通合伙）（以下简称 "天职国际"）为公司 2025 年度审计机构。具体内容详见公司 2025 年 4 月 26 日在上海证券交易所网站（www.sse.com.cn）披露的《关于续聘 2025 年度审计 机构的公告》（公告编号：2025-012）。 一、本次签字注册会计师变更的基本情况 天职国际作为 2025 年度财务报告审计机构与内部控制审计机构，原委派郭 海龙为项目合伙人、金园为签字注册会计师、张磊为项目质量复核人。由于天职 国际内部工作调整， ...

12月24日，赛伦生物涨0.36%，成交额955.29万元。两融数据显示，当日赛伦生物获融资买入额150.98 万元，融资偿还127.34万元，融资净买入23.64万元。截至12月24日，赛伦生物融资融券余额合计1.59亿 元。 融资方面，赛伦生物当日融资买入150.98万元。当前融资余额1.59亿元，占流通市值的6.65%，融资余 额超过近一年90%分位水平，处于高位。 分红方面，赛伦生物A股上市后累计派现2.48亿元。近三年，累计派现1.50亿元。 责任编辑：小浪快报 资料显示，上海赛伦生物技术股份有限公司位于上海市青浦区华青路1288号，成立日期1999年11月9 日，上市日期2022年3月11日，公司主营业务涉及研究、开发、生产及销售针对生物毒素及生物安全领 域的预防和治疗药物。主营业务收入构成为：抗血清抗毒素100.00%。 截至9月30日，赛伦生物股东户数6635.00，较上期减少14.10%；人均流通股16310股，较上期增加 183.92%。2025年1月-9月，赛伦生物实现营业收入1.75亿元，同比增长1.07%；归母净利润6421.07万 元，同比增长2.01%。 融券方面，赛伦生物12月 ...

资料显示，上海赛伦生物技术股份有限公司位于上海市青浦区华青路1288号，成立日期1999年11月9 日，上市日期2022年3月11日，公司主营业务涉及研究、开发、生产及销售针对生物毒素及生物安全领 域的预防和治疗药物。主营业务收入构成为：抗血清抗毒素100.00%。 截至9月30日，赛伦生物股东户数6635.00，较上期减少14.10%；人均流通股16310股，较上期增加 183.92%。2025年1月-9月，赛伦生物实现营业收入1.75亿元，同比增长1.07%；归母净利润6421.07万 元，同比增长2.01%。 12月23日，赛伦生物跌0.90%，成交额993.76万元。两融数据显示，当日赛伦生物获融资买入额159.02 万元，融资偿还85.96万元，融资净买入73.06万元。截至12月23日，赛伦生物融资融券余额合计1.58亿 元。 融资方面，赛伦生物当日融资买入159.02万元。当前融资余额1.58亿元，占流通市值的6.66%，融资余 额超过近一年80%分位水平，处于高位。 融券方面，赛伦生物12月23日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量0.00股 ...

证券日报网讯12月17日，赛伦生物在互动平台回答投资者提问时表示，截至目前，公司没有出口欧盟国 家的具体安排。 ...

Market Overview - The biopharmaceutical sector experienced a decline of 1.72% on December 2, with Aopumai leading the drop [1] - The Shanghai Composite Index closed at 3897.71, down 0.42%, while the Shenzhen Component Index closed at 13056.7, down 0.68% [1] Individual Stock Performance - Dongbao Bio (300239) closed at 5.80, up 1.05% with a trading volume of 93,700 shares and a transaction value of 53.99 million yuan [1] - Aopumai (688293) saw a significant drop of 8.01%, closing at 50.32 with a trading volume of 33,400 shares and a transaction value of 171 million yuan [2] - Other notable declines included Kanghong Pharmaceutical (002773) down 3.78% and Watson Bio (300142) down 3.17% [2] Capital Flow Analysis - The biopharmaceutical sector experienced a net outflow of 456 million yuan from institutional investors, while retail investors saw a net inflow of 270 million yuan [2] - Notable stocks with significant capital inflows included He Yuan Bio (688765) with a net inflow of 17.69 million yuan from institutional investors [3] - Conversely, stocks like Rongchang Bio (688331) and Shenzhou Cell (688520) also saw mixed capital flows, indicating varied investor sentiment [3]

Core Insights - The article highlights the significant advancements made by a Shanghai-based company, Sailun Biotech, in the field of biological toxin treatment, particularly in the development of antivenom for snake bites and other venomous injuries [1][2]. Group 1: Company Background and Development - Sailun Biotech was founded in 1999 and has evolved from a single product focus to a diversified portfolio, achieving a listing on the Sci-Tech Innovation Board [1][2]. - The company has been dedicated to the treatment of snake bites, which are a significant health crisis in China, with annual incidents ranging from 250,000 to 280,000 and a disability rate of 35.18% [2][3]. Group 2: Technological Advancements - The production of effective antivenom involves a complex and rigorous process, including toxin component analysis and large animal immunization, which Sailun Biotech has mastered over the years [3]. - The company is expanding its research and development efforts, with new projects underway for broad-spectrum antivenom and rapid diagnostic tests for snake venom, aiming to fill market gaps [3][4]. Group 3: Expansion into New Areas - Following success in snake antivenom, Sailun Biotech is venturing into the development of antivenom for bee stings, driven by a strong sense of social responsibility [4][5]. - The company is constructing a new research and production facility to enhance its capacity for large-scale production of these new products, expected to be completed by 2026 [4][5]. Group 4: Market Position and Future Plans - Sailun Biotech has made significant strides in innovation during the 14th Five-Year Plan, establishing platforms for rapid diagnostic tests and new antibody development [5][6]. - The company aims to enhance its market penetration and expand into international markets, leveraging its competitive pricing and quality advantages over foreign products [6][7].

Core Insights - The biopharmaceutical sector experienced a decline of 0.98% on November 18, with He Yuan Bio leading the drop [1] - The Shanghai Composite Index closed at 3939.81, down 0.81%, while the Shenzhen Component Index closed at 13080.49, down 0.92% [1] Stock Performance Summary - Notable gainers included: - Aopu Mai (688293) with a closing price of 58.80, up 3.38% on a trading volume of 15,900 shares and a transaction value of 93.39 million [1] - Jin Hu Ke (688670) at 26.80, up 2.88% with a volume of 116,300 shares and a transaction value of 319 million [1] - Te Bao Bio (688278) at 77.08, up 1.22% with a volume of 10,800 shares and a transaction value of 82.57 million [1] - Notable decliners included: - Bu Yuan Bio (688765) at 79.95, down 3.89% with a volume of 56,800 shares and a transaction value of 458 million [2] - San Sheng Guo Jian (688336) at 67.60, down 3.87% with a volume of 68,100 shares and a transaction value of 469 million [2] - Wo Wu Bio (300357) at 31.77, down 3.23% with a volume of 77,900 shares and a transaction value of 250 million [2] Capital Flow Analysis - The biopharmaceutical sector saw a net outflow of 981 million from institutional investors, while retail investors contributed a net inflow of 819 million [2] - Key stocks with significant capital flow included: - Hua Lan Vaccine (301207) with a net inflow of 48.51 million from institutional investors [3] - Rong Chang Bio (688331) with a net inflow of 23.62 million from institutional investors [3] - Jin Ke (688670) with a net inflow of 5.53 million from institutional investors [3]

Core Viewpoint - Siron Biotech's stock showed a slight increase of 0.65% on November 11, with a trading volume of 21.6453 million yuan, indicating stable market interest in the company [1]. Financing Summary - On November 11, Siron Biotech had a financing buy-in amount of 3.2277 million yuan and a financing repayment of 3.3749 million yuan, resulting in a net financing outflow of 0.1472 million yuan [1]. - The total financing and securities balance for Siron Biotech reached 161 million yuan, which accounts for 6.05% of its circulating market value, indicating a high level of financing activity compared to the past year [1]. - The company had no short-selling activity on November 11, with both short-selling repayment and selling amounts recorded at zero, reflecting a lack of bearish sentiment in the market [1]. Company Performance Summary - As of September 30, Siron Biotech had 6,635 shareholders, a decrease of 14.10% from the previous period, while the average number of circulating shares per shareholder increased by 183.92% to 16,310 shares [2]. - For the period from January to September 2025, Siron Biotech reported a revenue of 175 million yuan, representing a year-on-year growth of 1.07%, and a net profit attributable to shareholders of 64.2107 million yuan, which is a 2.01% increase year-on-year [2]. - Since its A-share listing, Siron Biotech has distributed a total of 248 million yuan in dividends, with 150 million yuan distributed over the past three years [2].